The Effect of Perioperative Dexamethasone Administration on Postoperative Pain in Patients Undergoing Periacetabular Osteotomy.

Model scores of the 29,894 trials active now.

Model score 10% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (112 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: No (raises risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: painhourskidneyto determine48
  Phrases that lowered it: the effecteffect ofpatients whocriteria patientsundergoing
• Sponsor's past termination rate: 4.7% (lowers risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 28 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 18.5% (lowers risk) · Drug's FDA history
• Number of arms: 3 (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 29718 (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Sponsor's past trials: 127 (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 192773 (lowers risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Perioperative Dexamethasone Reduces Postoperative Pain and Nausea After Hip Arthroscopy NCT04610398 · started 2021 · scored riskier than 16% of active trials completed
• Study To Investigate The Effectiveness Of Pregabalin For Management Of Patients Undergoing Total Hip Replacement NCT00905437 · started 2009 · scored riskier than 34% of active trials terminated
• Oral Treatment for Orthopaedic Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride NCT01902134 · started 2013 · scored riskier than 9% of active trials completed
• Pregabalin in the Prevention of Postoperative Delirium and Pain NCT00819988 · started 2009 · scored riskier than 15% of active trials completed
• Does Optimal Control of Pre-operative Chronic and Acute Pain Predict Improved Function After Orthopedic Surgery? NCT00581685 · started 2008 · scored riskier than 14% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.